Biomm S.A (BIOM3) - Total Liabilities
Based on the latest financial reports, Biomm S.A (BIOM3) has total liabilities worth R$200.93 Million BRL (≈ $39.43 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of Biomm S.A to track the company's year-over-year net asset growth rate.
Biomm S.A - Total Liabilities Trend (2004–2024)
This chart illustrates how Biomm S.A's total liabilities have evolved over time, based on quarterly financial data. See Biomm S.A free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Biomm S.A Competitors by Total Liabilities
The table below lists competitors of Biomm S.A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Saturn Metals Ltd
AU:STN
|
Australia | AU$2.96 Million |
|
SES AI Corp
NYSE:SES
|
USA | $50.27 Million |
|
Navkar Corporation Limited
NSE:NAVKARCORP
|
India | Rs2.52 Billion |
|
Sensorion SA
PA:ALSEN
|
France | €16.36 Million |
|
Cadence Capital Ltd
AU:CDM
|
Australia | AU$77.57 Million |
|
Gia Lai Electricity JSC
VN:GEG
|
Vietnam | ₫8.69 Trillion |
|
Macpower CNC Machines Limited
NSE:MACPOWER
|
India | Rs979.43 Million |
|
Wendell Industrial Co. Ltd
TWO:6761
|
Taiwan | NT$867.74 Million |
Liability Composition Analysis (2004–2024)
This chart breaks down Biomm S.A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see BIOM3 market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.45 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.11 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.71 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biomm S.A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biomm S.A (2004–2024)
The table below shows the annual total liabilities of Biomm S.A from 2004 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | R$202.88 Million ≈ $39.81 Million |
-8.52% |
| 2023-12-31 | R$221.76 Million ≈ $43.51 Million |
-9.85% |
| 2022-12-31 | R$245.98 Million ≈ $48.27 Million |
-4.75% |
| 2021-12-31 | R$258.25 Million ≈ $50.67 Million |
+6.06% |
| 2020-12-31 | R$243.49 Million ≈ $47.78 Million |
+3.52% |
| 2019-12-31 | R$235.21 Million ≈ $46.15 Million |
+17.85% |
| 2018-12-31 | R$199.59 Million ≈ $39.16 Million |
-1.72% |
| 2017-12-31 | R$203.09 Million ≈ $39.85 Million |
+18.45% |
| 2016-12-31 | R$171.46 Million ≈ $33.64 Million |
+49.68% |
| 2015-12-31 | R$114.55 Million ≈ $22.48 Million |
+58.07% |
| 2014-12-31 | R$72.46 Million ≈ $14.22 Million |
+148.65% |
| 2013-12-31 | R$29.14 Million ≈ $5.72 Million |
+0.48% |
| 2012-12-31 | R$29.00 Million ≈ $5.69 Million |
+44.59% |
| 2011-12-31 | R$20.06 Million ≈ $3.94 Million |
+123.68% |
| 2010-12-31 | R$8.97 Million ≈ $1.76 Million |
-15.96% |
| 2009-12-31 | R$10.67 Million ≈ $2.09 Million |
-56.24% |
| 2008-12-31 | R$24.39 Million ≈ $4.78 Million |
+104.31% |
| 2007-12-31 | R$11.94 Million ≈ $2.34 Million |
+47.94% |
| 2006-12-31 | R$8.07 Million ≈ $1.58 Million |
-36.13% |
| 2005-12-31 | R$12.63 Million ≈ $2.48 Million |
+137.98% |
| 2004-12-31 | R$5.31 Million ≈ $1.04 Million |
-- |
About Biomm S.A
Biomm S.A. operates as a biotechnology company in Brazil. The company offers insulin products for the treatment of diabetes, including AFREZZA, a Human insulin powder for inhalation; GLARGILIN, a glargine insulin; WOSULIN N and WOSULIN R; and Lifepen G, a reusable insulin injection pen. It also provides Bevyx for the treatment of metastatic colorectal cancer; HERZUMA for the treatment of early-st… Read more